MGF and PEG MGF Research: Mechano Growth Factor and IGF-1 Splice Variant Biology

MGF (Mechano Growth Factor) is a splice variant of the insulin-like growth factor 1 (IGF-1) gene that is produced specifically in response to mechanical stress and tissue damage. Unlike systemic IGF-1 produced primarily in the liver, MGF is generated locally in mechanically stimulated tissues — particularly skeletal muscle — through a specific alternative splicing event that generates a unique C-terminal E-peptide.

IGF-1 Gene Splicing and MGF Generation

The IGF-1 gene contains six exons. Alternative splicing of exons 4, 5, and 6 generates multiple IGF-1 isoforms with different C-terminal extensions (E-peptides) following the mature IGF-1 domain. The Eb isoform (in rodents, called the Ec isoform in humans) is specifically upregulated by mechanical loading, exercise, and injury — it was named Mechano Growth Factor by Yang and Goldspink to reflect this mechano-sensitive expression pattern.

The unique feature of MGF: its E-peptide sequence is completely different from the Ea isoform E-peptide. The MGF E-peptide (24 amino acids in the synthetic research form) does not contain the mature IGF-1 receptor binding domain and is studied for receptor-independent biological activities.

MGF E-Peptide: Distinct from IGF-1R Biology

This is the key research rationale for studying MGF as a separate tool from IGF-1 LR3:

IGF-1 LR3 activates IGF-1R through the classic receptor tyrosine kinase pathway (PI3K/Akt/mTOR, Ras/MAPK), driving protein synthesis and cell survival via well-characterised downstream cascades.

MGF E-peptide has been studied in the context of satellite cell (muscle stem cell) activation — a process distinct from IGF-1R-mediated anabolism. Published research has suggested that the E-peptide may act through a separate receptor or through nuclear localisation, activating satellite cells without requiring IGF-1R signalling. This proposed mechano-sensitive satellite cell activation mechanism is the focus of MGF research.

Yang and Goldspink (FEBS Letters, 2002) published that MGF E-peptide promoted satellite cell proliferation, and that this effect could be separated from IGF-1R-mediated effects — establishing MGF as a distinct research tool from conventional IGF-1 analogues.

PEGylation: Extending Half-Life for Research

Unmodified MGF E-peptide has an extremely short plasma half-life — estimated at just a few minutes — due to rapid proteolytic degradation and small molecular size enabling rapid renal clearance.

PEGylation (attachment of polyethylene glycol chains) addresses this limitation:

• Increased molecular size prevents glomerular filtration (above approximately 50 kDa cutoff)
• Steric bulk protects against proteolytic attack on the peptide backbone
• Reduced receptor-mediated clearance in some cases

The result is a half-life extension from minutes to several days for PEG MGF, enabling:

• Chronic dosing studies not feasible with native MGF
• Systemic delivery studies (unmodified MGF is cleared before reaching distant tissues)
• Comparison of acute (native MGF) versus chronic (PEG MGF) mechano-sensitive signalling

Research Design: MGF vs PEG MGF vs IGF-1 LR3

Published Research References

For laboratory and analytical research purposes only. Not for human or veterinary use.

Related: IGF-1 LR3 | PEG MGF | Adipotide (FTPP)
View MGF product and buy →

IGF-1 Splice Variants: The Complete Picture

Understanding MGF's position within the IGF-1 splice variant family provides essential research context. The IGF1 gene generates multiple isoforms through alternative splicing of exons 4, 5, and 6, with the most important distinction being the E-peptide sequence following the mature IGF-1 domain:

IGF-1Ea (Class 1 or IGF-1A): Uses exon 6 for the E-peptide. This is the primary circulating IGF-1 isoform, produced predominantly in liver in response to GH stimulation. The Ea E-peptide is rapidly cleaved from the mature IGF-1 domain by proteases in the circulation, generating free mature IGF-1 that interacts with IGFBPs.

IGF-1Eb (Class 2, rodents) / IGF-1Ec (humans): Uses a frameshift in exon 5 followed by exon 6, generating a unique E-peptide. This is MGF — the mechano-sensitive isoform specifically upregulated in skeletal muscle, cardiac muscle, and other tissues following mechanical strain, exercise, or injury. The Eb/Ec E-peptide is not cleaved as rapidly as the Ea E-peptide, allowing the intact MGF pro-peptide to interact with cell surface receptors before mature IGF-1 is released.

This distinction is research-critical: MGF is not simply a tissue-generated form of IGF-1. It is a distinct isoform with a unique E-peptide domain that has been proposed to signal through mechanisms independent of the mature IGF-1/IGF-1R axis.

Satellite Cell Activation Pathway

Published research on MGF E-peptide in satellite cell activation has examined the mechanism connecting MGF to muscle stem cell proliferation. Satellite cells are normally quiescent, anchored beneath the basal lamina of muscle fibres, held in G0 by Notch signalling and other quiescence-maintaining signals.

Mechanical damage or exercise disrupts basal lamina integrity and releases MGF locally. Published data suggests MGF E-peptide — before the mature IGF-1 domain is released — activates a signalling pathway in satellite cells that drives them from quiescence into G1 (cell cycle entry). The specific receptor responsible for MGF E-peptide activation of satellite cells has not been definitively identified, though research has examined HSPG interactions (heparan sulphate proteoglycans), which could serve as co-receptors presenting the E-peptide to an as-yet-uncharacterised transmembrane receptor.

Frequently Asked Questions

How should researchers choose between MGF and PEG MGF for their research design?
The choice depends on the research question and experimental system. For acute mechano-sensitive signalling studies where a single, defined MGF stimulus is applied and effects are measured within hours, native MGF is appropriate — its rapid clearance ensures a defined exposure window. For chronic studies examining sustained MGF signalling over days (satellite cell proliferation over multiple days, chronic muscle adaptation paradigms), PEG MGF is preferable because its extended half-life maintains MGF activity without repeated dosing. For in vivo research where systemic distribution of MGF is important (rather than local injection effects), PEG MGF's size advantage in avoiding renal clearance makes it the appropriate choice.

Is there a way to separate MGF E-peptide effects from mature IGF-1 effects in research experiments?
Using the isolated synthetic MGF C-terminal peptide (as supplied by Signal Labs) rather than full-length recombinant MGF pro-peptide allows examination of E-peptide specific biology. The synthetic peptide lacks the mature IGF-1 domain entirely and therefore cannot activate IGF-1R — any observed effects are attributable to the E-peptide sequence. Parallel experiments with mature IGF-1 LR3 (which activates IGF-1R but lacks the E-peptide) allow direct comparison of E-peptide-specific versus IGF-1R-mediated effects on the same endpoint.

Browse all Signal Labs research peptides | Peptide storage guide | Reconstitution guide

MGF and PEG MGF: Storage and Reconstitution

MGF and PEG MGF have different physical properties that affect their handling:

Native MGF E-peptide: As a small synthetic peptide (24 amino acids, approximately 2.8 kDa), MGF E-peptide is lyophilised as a white powder with good aqueous solubility. Reconstitute in bacteriostatic water at 1mg/mL. Store reconstituted solutions at -20°C in single-use aliquots — MGF's short biological half-life (minutes in plasma) does not reflect instability of the reconstituted peptide stock, which is stable at -20°C for months.

PEG MGF: The PEGylated form has substantially higher molecular weight (the PEG chain adds 2-40 kDa depending on PEG size) and different solubility characteristics. PEG MGF lyophilised powder may appear slightly different in texture from native MGF due to the large hydrophilic PEG portion. Reconstitution in bacteriostatic water or sterile PBS is appropriate. PEG MGF solutions may be slightly more viscous than equivalent mass/volume MGF solutions due to the PEG polymer contribution to solution viscosity.

Stability comparison: PEG MGF in biological media (serum-containing cell culture, plasma) is substantially more stable than native MGF due to protease resistance from steric shielding by the PEG chain. For long-duration experiments (greater than 4 hours), PEG MGF maintains more consistent effective concentrations in biological media — use PEG MGF rather than native MGF when extended incubation stability is required.